Results 161 to 170 of about 436,550 (248)

Severe nausea and vomiting after teprotumumab initiation with corticosteroid pretreatment: a case report. [PDF]

Int J Ophthalmol
Youn J, Firn K, Hawy E, Van Putten D.
europepmc   +1 more source

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

Cancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna, Medina Esenbekova, Micheal Bishara, Layo Akinrinwoye, Joane Titus, Leila Metellus   +5 more
wiley   +1 more source

La pobreza del más rico. Nietzsche y el problema de la donación [PDF]

, 1996
Pascual, Sebastià M.
core  

Efficacy and safety of transcutaneous electrical acupoint stimulation and acupressure in alleviating chemotherapy-related adverse reactions in female patients with breast cancer: a randomized clinical trial. [PDF]

Front Oncol
Yuan J, Chu J, Hu X, Zhao X, Li H, Zhang B, Baihong L, Han J, Tao Z, Kayishaer T, Tian C, Zhu B, Yang Y.   +12 more
europepmc   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Eficacia y seguridad de la Buprenorfina Transdérmica / Ketorolaco Intravenoso vs Tramadol / Ketorolaco Intravenoso para Analgesia postoperatoria en pacientes sometidos a reemplazo total de Rodilla en el Centro Médico ISSEMyM [PDF]

, 2014
Campos Fernández, María Guadalupe Isabel, Osorio Solorio, Lyly Melissa   +1 more
core  

Acupuncture Therapies for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: Protocol for a Systematic Review and Network Meta-Analysis. [PDF]

JMIR Res Protoc
Luo Y, Bian Z, Wang Q, Lei T, Zhao H.
europepmc   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

"Total nausea" as a manifestation of "total pain" and an expression of suffering: a case report. [PDF]

J Med Case Rep
Volberg C, Janke R, Erk M, Riera-Knorrenschild J, Toussaint K.   +4 more
europepmc   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source